GSK plc（GSK）適時開示・決算発表
| 提出日 | 様式 | 項目 | 原文 |
|---|---|---|---|
| 2026-10-08 | 6-K | WENDY BECKER CBE - NEW DIRECTORSHIP | SEC |
| 2026-10-06 | 6-K | ADMISSION TO TRADING | SEC |
| 2026-10-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-09-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-15 | 6-K | — | SEC |
| 2026-09-15 | 6-K | GSK TO ACQUIRE T CELL-ENGAGER FOR MULTIPLE MYELOMA | SEC |
| 2026-09-14 | 6-K | JIDEYTRO POSITIVE DATA FOR ROS1-POSITIVE NSCLC | SEC |
| 2026-09-14 | 6-K | RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA | SEC |
| 2026-09-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-10 | 6-K | JAPAN APPROVAL OF SHINGRIX IN A PREFILLED SYRINGE | SEC |
| 2026-09-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-09-08 | 6-K | — | SEC |
| 2026-09-01 | 6-K | MRNA FLU VACCINE CANDIDATE TO ADVANCE TO PHASE III | SEC |
| 2026-09-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-08-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-24 | 6-K | US FDA TO REVIEW JEMPERLI FOR RECTAL CANCER | SEC |
| 2026-08-24 | 6-K | FIRST GLOBAL APPROVAL FOR HIBSAGO IN JAPAN | SEC |
| 2026-08-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-08-03 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-07-30 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-28 | 6-K | 2ND QUARTER RESULTS | SEC |
| 2026-07-28 | 6-K | HANSOH POSITIVE 2ND PHASE III RESULTS FOR RIZ-REZ | SEC |
| 2026-07-28 | 6-K | NEW GSK FLAGSHIP R&D CENTRE IN CAMBRIDGE | SEC |
| 2026-07-24 | 6-K | ADMISSION TO TRADING | SEC |
| 2026-07-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-22 | 6-K | JIDEYTRO APPROVED IN US FOR CERTAIN LUNG CANCERS | SEC |
| 2026-07-20 | 6-K | BEXSERO 1-DOSE BOOSTER EMA FILE ACCEPTANCE | SEC |
| 2026-07-17 | 6-K | CAMLIPIXANT PHASE III RESULTS UPDATE | SEC |
| 2026-07-17 | 6-K | AUDIT TENDER CONCLUSION | SEC |
| 2026-07-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-15 | 6-K | GSK COMPLETES ACQUISITION OF NUVALENT, INC | SEC |
| 2026-07-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-13 | 6-K | POSITIVE JEMPERLI DATA IN DMMR/MSI-H RECTAL CANCER | SEC |
| 2026-07-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-10 | 6-K | HANSOH POSITIVE PHASE III RESULTS FOR RIZ-REZ | SEC |
| 2026-07-09 | 6-K | DIRECTORATE CHANGE | SEC |
| 2026-07-09 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-07-01 | 6-K | TOTAL VOTING RIGHTS | SEC |
| 2026-06-29 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2026-06-29 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-26 | 6-K | HOLDING(S) IN COMPANY | SEC |
| 2026-06-24 | 6-K | GSK ANNOUNCES TENDER OFFER TO ACQUIRE NUVALENT | SEC |
| 2026-06-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-22 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-17 | 6-K | CUTI ORAL ANTIBIOTIC TEBIPENEM APPROVED BY US FDA | SEC |
| 2026-06-15 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-12 | 6-K | MOMELOTINIB ORPHAN DRUG DESIGNATIONS FOR VEXAS | SEC |
| 2026-06-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-10 | 6-K | DIRECTOR/PDMR SHAREHOLDING | SEC |
| 2026-06-09 | 6-K | GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. | SEC |
| 2026-06-09 | 6-K | DR HAL BARRON - NEW DIRECTORSHIP | SEC |
| 2026-06-08 | 6-K | TRANSACTION IN OWN SHARES | SEC |
| 2026-06-01 | 6-K | TRANSACTION IN OWN SHARES | SEC |
出典は SEC EDGAR の 8-K／6-K。8-K は米国内企業の臨時報告（Item 2.02 が決算発表）、6-K は外国企業（ADR 含む）の対応様式です。当サイトはリンクの整理のみ行い、原文はすべて sec.gov にあります。「動画」は会社のプレスリリースに記載された決算説明会 webcast の URL、「IR ページ」はプレスリリースが案内している会社の IR ページで、リプレイの公開期間は限られます。決算説明会の日時は同じプレスリリースの記載どおりで、米国現地時間（ET 東部・CT 中部・MT 山岳部・PT 太平洋）です。